Secukinumab real world drug retention compared to TNF-alpha inhibitors in psoriatic arthritis

Tali Eviatar, Devy Zisman, Omer Gendelman, Tatiana Reitblat, Alexandra Balbir-Gurman, Tanya Mashiach, Ronit Almog, Ori Elkayam

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To prospectively study real-world efficacy and safety of secukinumab in psoriatic arthritis (PsA) patients from the Israeli registry of inflammatory diseases. Methods: PsA patients fulfilling the CASPAR criteria were included in the analysis from 2010 to 2019. The primary endpoint was secukinumab drug retention compared to other TNF-α inhibitors (TNFi). Bivariate and multivariate analyses were made by Cox regression analysis. Drug retention according to treatment line was examined with Kaplan-Meier curves. Results: Included were 404 PsA patients who had 709 treatment courses during the study period. Ninety patients had been treated with secukinumab (22%). The secukinumab-treated patients were significantly older and their disease duration was longer. Secukinumab was less likely to be the first line of treatment compared to TNFi. Secukinumab had a drug retention comparable to TNFi, and a better drug retention than TNFi among biologic-experienced patients. Neither methotrexate combination nor body mass index affected the inefficacy event rate. Secukinumab had a similar rate of adverse events as TNFi. Conclusion: This multicentre real-world study demonstrated that secukinumab had a drug retention comparable to TNFi. Secukinumab had a better drug retention than TNFi among biologic-experienced patients. IL-17 inhibition is an effective mechanism of action to treat PsA in real life.

Original languageEnglish
Pages (from-to)15-23
Number of pages9
JournalClinical and Experimental Rheumatology
Volume40
Issue number1
StatePublished - Jan 2022
Externally publishedYes

Bibliographical note

Publisher Copyright:
© Copyright Clinical and Experimental Rheumatology 2022.

Keywords

  • Drug retention
  • Psoriatic arthritis
  • Real-world
  • Secukinumab
  • TNFα inhibitors

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology

Fingerprint

Dive into the research topics of 'Secukinumab real world drug retention compared to TNF-alpha inhibitors in psoriatic arthritis'. Together they form a unique fingerprint.

Cite this